UNSPSC 51341502: Fosamprenavir

This classification denotes a protease inhibitor with the molecular formula C25H36N3O9PS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WOU1621EEG, chemically known as carbamic acid, ((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, c-((3s)-tetrahydro-3-furanyl) ester but generally known as fosamprenavir, which bears US NIH Compound Identifier 131536.

UNSPSC 51341502 Fosamprenavir is a Commodity code that nominally references a specific antiretroviral pharmaceutical, but recent state and local opportunities show no activity aligned with fosamprenavir procurement itself. The code appears dormant or misapplied in the active state and local solicitation ecosystem as of mid-2026. The recent opportunities tagged to this code span pharmaceutical procurement broadly—naloxone and drug deactivation systems, multi-source generic pharmaceuticals and OTC products, and therapeutic pharmacy direct-to-manufacturer initiatives—none of which are antiretroviral medications or fosamprenavir specifically. This mismatch suggests the code may not be the appropriate UNSPSC category for the work being solicited, or the code assignment reflects a data classification error rather than genuine procurement activity under the fosamprenavir commodity itself.

Recent activity includes an IFB from Seminole County, Florida (posted June 30, 2026, due July 26, 2023) for naloxone and drug deactivation systems; an RFI from the Texas Health and Human Services Commission (posted April 3, 2026) exploring direct-to-manufacturer prescription programs; an IFB from the City of Tampa (posted March 25, 2026, due March 13, 2026) for medical and first aid supplies totaling approximately $700,000 with Small Local Business Enterprise set-asides; and an RFP from the Minnesota Multistate Cooperative Purchasing Alliance (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across state and local facilities. Activity clusters in Florida, Texas, and Minnesota, with cooperative purchasing mechanisms featuring prominently. The code shows minimal relevance to businesses focused on antiretroviral or HIV-treatment pharmaceuticals and warrants reclassification review before committing pursuit strategy around it.